Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide

NCT ID: NCT00279045

Last Updated: 2017-11-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

4426 participants

Study Classification

INTERVENTIONAL

Study Start Date

2000-01-03

Study Completion Date

2006-06-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will compare and evaluate the effects of long-term treatment of monotherapy with rosiglitazone, metformin and glyburide/glibenclamide on the improvement and maintenance of glycemic control in patients with recently diagnosed type 2 diabetes mellitus.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

type 2 diabetes monotherapy treatment naive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rosiglitazone

Intervention Type DRUG

glyburide

Intervention Type DRUG

metformin

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

glyburide Rosiglitazone

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Newly diagnosed patients (\< 3years) with type 2 diabetes.
* Fasting plasma glucose (FPG) range of 126-240 mg/dL at Screening.
* No previous treatment with oral or parenteral glucose-lowering therapy.

Exclusion Criteria

* History of lactic acidosis.
* Anemia (\<11g for males, \<10 g for females).
* Unstable or severe NY Heart Association-class 3 or 4.
* Any NY Heart Association congestive heart failure.
* Patients with chronic diseases requiring periodic or intermittent treatment with oral or intravenous corticosteroids.
Minimum Eligible Age

30 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GlaxoSmithKline

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GSK Investigational Site

Doncaster, , United Kingdom

Site Status

GSK Investigational Site

Doncaster, , United Kingdom

Site Status

GSK Investigational Site

Gateshead, , United Kingdom

Site Status

GSK Investigational Site

Glasgow, , United Kingdom

Site Status

GSK Investigational Site

Glenrothes, , United Kingdom

Site Status

GSK Investigational Site

Irvine, , United Kingdom

Site Status

GSK Investigational Site

Kent, , United Kingdom

Site Status

GSK Investigational Site

Leicester, , United Kingdom

Site Status

GSK Investigational Site

London, , United Kingdom

Site Status

GSK Investigational Site

London, , United Kingdom

Site Status

GSK Investigational Site

Newtownabbey, , United Kingdom

Site Status

GSK Investigational Site

Peterborough, , United Kingdom

Site Status

GSK Investigational Site

Swansea, , United Kingdom

Site Status

GSK Investigational Site

Wakefield, , United Kingdom

Site Status

GSK Investigational Site

Wigan, , United Kingdom

Site Status

GSK Investigational Site

Nuneaton, Warwickshire, United Kingdom

Site Status

GSK Investigational Site

Rugby, Warwickshire, United Kingdom

Site Status

GSK Investigational Site

Livingston, West Lothian, United Kingdom

Site Status

GSK Investigational Site

Cardiff, , United Kingdom

Site Status

GSK Investigational Site

Co.Antrim, , United Kingdom

Site Status

GSK Investigational Site

Melksham, Wiltshire, United Kingdom

Site Status

GSK Investigational Site

Trowbridge, Wiltshire, United Kingdom

Site Status

GSK Investigational Site

Barnsley, , United Kingdom

Site Status

GSK Investigational Site

Anniston, Alabama, United States

Site Status

GSK Investigational Site

Birmingham, Alabama, United States

Site Status

GSK Investigational Site

Mesa, Arizona, United States

Site Status

GSK Investigational Site

Tucson, Arizona, United States

Site Status

GSK Investigational Site

Little Rock, Arkansas, United States

Site Status

GSK Investigational Site

Berkeley, California, United States

Site Status

GSK Investigational Site

Corona, California, United States

Site Status

GSK Investigational Site

Fair Oaks, California, United States

Site Status

GSK Investigational Site

Fremont, California, United States

Site Status

GSK Investigational Site

Fresno, California, United States

Site Status

GSK Investigational Site

Fullerton, California, United States

Site Status

GSK Investigational Site

Greenbrae, California, United States

Site Status

GSK Investigational Site

Harbor City, California, United States

Site Status

GSK Investigational Site

Healdsburg, California, United States

Site Status

GSK Investigational Site

La Jolla, California, United States

Site Status

GSK Investigational Site

Bath, , United Kingdom

Site Status

GSK Investigational Site

Loma Linda, California, United States

Site Status

GSK Investigational Site

Los Angeles, California, United States

Site Status

GSK Investigational Site

Los Angeles, California, United States

Site Status

GSK Investigational Site

Modesto, California, United States

Site Status

GSK Investigational Site

Pasadena, California, United States

Site Status

GSK Investigational Site

San Diego, California, United States

Site Status

GSK Investigational Site

San Francisco, California, United States

Site Status

GSK Investigational Site

Santa Rosa, California, United States

Site Status

GSK Investigational Site

Sunnyvale, California, United States

Site Status

GSK Investigational Site

Ukiah, California, United States

Site Status

GSK Investigational Site

Walnut Creek, California, United States

Site Status

GSK Investigational Site

Yorba Linda, California, United States

Site Status

GSK Investigational Site

Boulder, Colorado, United States

Site Status

GSK Investigational Site

Denver, Colorado, United States

Site Status

GSK Investigational Site

Denver, Colorado, United States

Site Status

GSK Investigational Site

Englewood, Colorado, United States

Site Status

GSK Investigational Site

Longmont, Colorado, United States

Site Status

GSK Investigational Site

Wheat Ridge, Colorado, United States

Site Status

GSK Investigational Site

Wheat Ridge, Colorado, United States

Site Status

GSK Investigational Site

Washington D.C., District of Columbia, United States

Site Status

GSK Investigational Site

Washington D.C., District of Columbia, United States

Site Status

GSK Investigational Site

Fort Myers, Florida, United States

Site Status

GSK Investigational Site

Hollywood, Florida, United States

Site Status

GSK Investigational Site

Jacksonville, Florida, United States

Site Status

GSK Investigational Site

Jacksonville, Florida, United States

Site Status

GSK Investigational Site

Melbourne, Florida, United States

Site Status

GSK Investigational Site

Miami, Florida, United States

Site Status

GSK Investigational Site

Miami, Florida, United States

Site Status

GSK Investigational Site

Orlando, Florida, United States

Site Status

GSK Investigational Site

Palm Harbor, Florida, United States

Site Status

GSK Investigational Site

Sarasota, Florida, United States

Site Status

GSK Investigational Site

St. Petersburg, Florida, United States

Site Status

GSK Investigational Site

St. Petersburg, Florida, United States

Site Status

GSK Investigational Site

Tampa, Florida, United States

Site Status

GSK Investigational Site

Titusville, Florida, United States

Site Status

GSK Investigational Site

West Palm Beach, Florida, United States

Site Status

GSK Investigational Site

Atlanta, Georgia, United States

Site Status

GSK Investigational Site

Atlanta, Georgia, United States

Site Status

GSK Investigational Site

Atlanta, Georgia, United States

Site Status

GSK Investigational Site

Atlanta, Georgia, United States

Site Status

GSK Investigational Site

Atlanta, Georgia, United States

Site Status

GSK Investigational Site

Blue Ridge, Georgia, United States

Site Status

GSK Investigational Site

Dunwoody, Georgia, United States

Site Status

GSK Investigational Site

Fayetteville, Georgia, United States

Site Status

GSK Investigational Site

Honolulu, Hawaii, United States

Site Status

GSK Investigational Site

Boise, Idaho, United States

Site Status

GSK Investigational Site

Chicago, Illinois, United States

Site Status

GSK Investigational Site

Gurnee, Illinois, United States

Site Status

GSK Investigational Site

Springfield, Illinois, United States

Site Status

GSK Investigational Site

Evansville, Indiana, United States

Site Status

GSK Investigational Site

Indianapolis, Indiana, United States

Site Status

GSK Investigational Site

Indianapolis, Indiana, United States

Site Status

GSK Investigational Site

Lexington, Kentucky, United States

Site Status

GSK Investigational Site

Lake Charles, Louisiana, United States

Site Status

GSK Investigational Site

New Orleans, Louisiana, United States

Site Status

GSK Investigational Site

Slidell, Louisiana, United States

Site Status

GSK Investigational Site

Slidell, Louisiana, United States

Site Status

GSK Investigational Site

Bangor, Maine, United States

Site Status

GSK Investigational Site

Baltimore, Maryland, United States

Site Status

GSK Investigational Site

Baltimore, Maryland, United States

Site Status

GSK Investigational Site

Baltimore, Maryland, United States

Site Status

GSK Investigational Site

Baltimore, Maryland, United States

Site Status

GSK Investigational Site

Boston, Massachusetts, United States

Site Status

GSK Investigational Site

Springfield, Massachusetts, United States

Site Status

GSK Investigational Site

Ann Arbor, Michigan, United States

Site Status

GSK Investigational Site

Detroit, Michigan, United States

Site Status

GSK Investigational Site

Lansing, Michigan, United States

Site Status

GSK Investigational Site

Royal Oak, Michigan, United States

Site Status

GSK Investigational Site

Minneapolis, Minnesota, United States

Site Status

GSK Investigational Site

Minneapolis, Minnesota, United States

Site Status

GSK Investigational Site

Minneapolis, Minnesota, United States

Site Status

GSK Investigational Site

Jackson, Mississippi, United States

Site Status

GSK Investigational Site

Olive Branch, Mississippi, United States

Site Status

GSK Investigational Site

Kansas City, Missouri, United States

Site Status

GSK Investigational Site

St Louis, Missouri, United States

Site Status

GSK Investigational Site

St Louis, Missouri, United States

Site Status

GSK Investigational Site

Billings, Montana, United States

Site Status

GSK Investigational Site

Omaha, Nebraska, United States

Site Status

GSK Investigational Site

Omaha, Nebraska, United States

Site Status

GSK Investigational Site

Henderson, Nevada, United States

Site Status

GSK Investigational Site

Cherry Hill, New Jersey, United States

Site Status

GSK Investigational Site

Cherry Hill, New Jersey, United States

Site Status

GSK Investigational Site

Albuquerque, New Mexico, United States

Site Status

GSK Investigational Site

Albuquerque, New Mexico, United States

Site Status

GSK Investigational Site

Albuquerque, New Mexico, United States

Site Status

GSK Investigational Site

Albany, New York, United States

Site Status

GSK Investigational Site

Endwell, New York, United States

Site Status

GSK Investigational Site

Flushing, New York, United States

Site Status

GSK Investigational Site

New York, New York, United States

Site Status

GSK Investigational Site

New York, New York, United States

Site Status

GSK Investigational Site

New York, New York, United States

Site Status

GSK Investigational Site

New York, New York, United States

Site Status

GSK Investigational Site

New York, New York, United States

Site Status

GSK Investigational Site

Rochester, New York, United States

Site Status

GSK Investigational Site

Rochester, New York, United States

Site Status

GSK Investigational Site

Syracuse, New York, United States

Site Status

GSK Investigational Site

The Bronx, New York, United States

Site Status

GSK Investigational Site

Durham, North Carolina, United States

Site Status

GSK Investigational Site

Cincinnati, Ohio, United States

Site Status

GSK Investigational Site

Cleveland, Ohio, United States

Site Status

GSK Investigational Site

Cleveland, Ohio, United States

Site Status

GSK Investigational Site

Mogadore, Ohio, United States

Site Status

GSK Investigational Site

Westlake, Ohio, United States

Site Status

GSK Investigational Site

Oklahoma City, Oklahoma, United States

Site Status

GSK Investigational Site

Bend, Oregon, United States

Site Status

GSK Investigational Site

Eugene, Oregon, United States

Site Status

GSK Investigational Site

Portland, Oregon, United States

Site Status

GSK Investigational Site

Portland, Oregon, United States

Site Status

GSK Investigational Site

Downingtown, Pennsylvania, United States

Site Status

GSK Investigational Site

Feasterville, Pennsylvania, United States

Site Status

GSK Investigational Site

Fleetwood, Pennsylvania, United States

Site Status

GSK Investigational Site

Hermitage, Pennsylvania, United States

Site Status

GSK Investigational Site

Hershey, Pennsylvania, United States

Site Status

GSK Investigational Site

Jefferson Hills, Pennsylvania, United States

Site Status

GSK Investigational Site

Philadelphia, Pennsylvania, United States

Site Status

GSK Investigational Site

Philadelphia, Pennsylvania, United States

Site Status

GSK Investigational Site

Philadelphia, Pennsylvania, United States

Site Status

GSK Investigational Site

Philadelphia, Pennsylvania, United States

Site Status

GSK Investigational Site

Pittsburgh, Pennsylvania, United States

Site Status

GSK Investigational Site

Upland, Pennsylvania, United States

Site Status

GSK Investigational Site

Warminster, Pennsylvania, United States

Site Status

GSK Investigational Site

West Chester, Pennsylvania, United States

Site Status

GSK Investigational Site

Charleston, South Carolina, United States

Site Status

GSK Investigational Site

Columbia, South Carolina, United States

Site Status

GSK Investigational Site

Greer, South Carolina, United States

Site Status

GSK Investigational Site

Spartanburg, South Carolina, United States

Site Status

GSK Investigational Site

Bristol, Tennessee, United States

Site Status

GSK Investigational Site

Nashville, Tennessee, United States

Site Status

GSK Investigational Site

Arlington, Texas, United States

Site Status

GSK Investigational Site

Austin, Texas, United States

Site Status

GSK Investigational Site

Beaumont, Texas, United States

Site Status

GSK Investigational Site

Corpus Christi, Texas, United States

Site Status

GSK Investigational Site

Corpus Christi, Texas, United States

Site Status

GSK Investigational Site

Dallas, Texas, United States

Site Status

GSK Investigational Site

Dallas, Texas, United States

Site Status

GSK Investigational Site

Dallas, Texas, United States

Site Status

GSK Investigational Site

Fort Worth, Texas, United States

Site Status

GSK Investigational Site

Houston, Texas, United States

Site Status

GSK Investigational Site

Houston, Texas, United States

Site Status

GSK Investigational Site

Irving, Texas, United States

Site Status

GSK Investigational Site

Midland, Texas, United States

Site Status

GSK Investigational Site

San Antonio, Texas, United States

Site Status

GSK Investigational Site

San Antonio, Texas, United States

Site Status

GSK Investigational Site

Ogden, Utah, United States

Site Status

GSK Investigational Site

Salt Lake City, Utah, United States

Site Status

GSK Investigational Site

Salt Lake City, Utah, United States

Site Status

GSK Investigational Site

Charlottesville, Virginia, United States

Site Status

GSK Investigational Site

Newport News, Virginia, United States

Site Status

GSK Investigational Site

Richmond, Virginia, United States

Site Status

GSK Investigational Site

Salem, Virginia, United States

Site Status

GSK Investigational Site

Federal Way, Washington, United States

Site Status

GSK Investigational Site

Seattle, Washington, United States

Site Status

GSK Investigational Site

Seattle, Washington, United States

Site Status

GSK Investigational Site

Seattle, Washington, United States

Site Status

GSK Investigational Site

Spokane, Washington, United States

Site Status

GSK Investigational Site

Spokane, Washington, United States

Site Status

GSK Investigational Site

Spokane, Washington, United States

Site Status

GSK Investigational Site

Wenatchee, Washington, United States

Site Status

GSK Investigational Site

Charleston, West Virginia, United States

Site Status

GSK Investigational Site

Huntington, West Virginia, United States

Site Status

GSK Investigational Site

Madison, Wisconsin, United States

Site Status

GSK Investigational Site

Milwaukee, Wisconsin, United States

Site Status

GSK Investigational Site

Oregon, Wisconsin, United States

Site Status

GSK Investigational Site

Vienna, , Austria

Site Status

GSK Investigational Site

Vienna, , Austria

Site Status

GSK Investigational Site

Wiener Neustadt, , Austria

Site Status

GSK Investigational Site

Blankenberge, , Belgium

Site Status

GSK Investigational Site

Boechout, , Belgium

Site Status

GSK Investigational Site

Deurne, , Belgium

Site Status

GSK Investigational Site

Leuven, , Belgium

Site Status

GSK Investigational Site

Lubbeek (Linden), , Belgium

Site Status

GSK Investigational Site

Tielt, , Belgium

Site Status

GSK Investigational Site

Wezembeek-Oppem, , Belgium

Site Status

GSK Investigational Site

Wijnegem, , Belgium

Site Status

GSK Investigational Site

Zemst, , Belgium

Site Status

GSK Investigational Site

Calgary, Alberta, Canada

Site Status

GSK Investigational Site

Edmonton, Alberta, Canada

Site Status

GSK Investigational Site

Edmonton, Alberta, Canada

Site Status

GSK Investigational Site

Red Deer, Alberta, Canada

Site Status

GSK Investigational Site

Coquitlam, British Columbia, Canada

Site Status

GSK Investigational Site

Vancouver, British Columbia, Canada

Site Status

GSK Investigational Site

Victoria, British Columbia, Canada

Site Status

GSK Investigational Site

Winnipeg, Manitoba, Canada

Site Status

GSK Investigational Site

Winnipeg, Manitoba, Canada

Site Status

GSK Investigational Site

Cambellton, New Brunswick, Canada

Site Status

GSK Investigational Site

Moncton, New Brunswick, Canada

Site Status

GSK Investigational Site

St. John's, Newfoundland and Labrador, Canada

Site Status

GSK Investigational Site

Antigonish, Nova Scotia, Canada

Site Status

GSK Investigational Site

Halifax, Nova Scotia, Canada

Site Status

GSK Investigational Site

Burlington, Ontario, Canada

Site Status

GSK Investigational Site

Greater Sudbury, Ontario, Canada

Site Status

GSK Investigational Site

Kingston, Ontario, Canada

Site Status

GSK Investigational Site

London, Ontario, Canada

Site Status

GSK Investigational Site

Mississauga, Ontario, Canada

Site Status

GSK Investigational Site

Oakville, Ontario, Canada

Site Status

GSK Investigational Site

Ottawa, Ontario, Canada

Site Status

GSK Investigational Site

Thornhill, Ontario, Canada

Site Status

GSK Investigational Site

Thunder Bay, Ontario, Canada

Site Status

GSK Investigational Site

Timmins, Ontario, Canada

Site Status

GSK Investigational Site

Toronto, Ontario, Canada

Site Status

GSK Investigational Site

Windsor, Ontario, Canada

Site Status

GSK Investigational Site

Charlottetown, Prince Edward Island, Canada

Site Status

GSK Investigational Site

Chicoutimi, Quebec, Canada

Site Status

GSK Investigational Site

La Malbaie, Quebec, Canada

Site Status

GSK Investigational Site

Laval, Quebec, Canada

Site Status

GSK Investigational Site

Montreal, Quebec, Canada

Site Status

GSK Investigational Site

Montreal, Quebec, Canada

Site Status

GSK Investigational Site

Plessisville, Quebec, Canada

Site Status

GSK Investigational Site

Saint-Marc-des-Carrieres, Quebec, Canada

Site Status

GSK Investigational Site

Sainte-Foy, Quebec, Canada

Site Status

GSK Investigational Site

Sherbrooke, Quebec, Canada

Site Status

GSK Investigational Site

St-Isidore de Dorchester, Quebec, Canada

Site Status

GSK Investigational Site

Regina, Saskatchewan, Canada

Site Status

GSK Investigational Site

Saskatoon, Saskatchewan, Canada

Site Status

GSK Investigational Site

Ostrava, , Czechia

Site Status

GSK Investigational Site

Phaha 5, , Czechia

Site Status

GSK Investigational Site

Prague, , Czechia

Site Status

GSK Investigational Site

Ústí nad Labem, , Czechia

Site Status

GSK Investigational Site

Zlín, , Czechia

Site Status

GSK Investigational Site

Frederiksberg C, , Denmark

Site Status

GSK Investigational Site

Odense, , Denmark

Site Status

GSK Investigational Site

Hanko, , Finland

Site Status

GSK Investigational Site

Helsinki, , Finland

Site Status

GSK Investigational Site

Jyväskylä, , Finland

Site Status

GSK Investigational Site

Lmatra, , Finland

Site Status

GSK Investigational Site

Savitaipale, , Finland

Site Status

GSK Investigational Site

Alben, , France

Site Status

GSK Investigational Site

Bezier, , France

Site Status

GSK Investigational Site

Bourges, , France

Site Status

GSK Investigational Site

Brogile, , France

Site Status

GSK Investigational Site

Chartres, , France

Site Status

GSK Investigational Site

Denguin, , France

Site Status

GSK Investigational Site

Évreux, , France

Site Status

GSK Investigational Site

Gamarde-les-Bains, , France

Site Status

GSK Investigational Site

La Rochelle, , France

Site Status

GSK Investigational Site

Labarthe-sur-Lèze, , France

Site Status

GSK Investigational Site

Le Mans, , France

Site Status

GSK Investigational Site

Le Pian-Médoc, , France

Site Status

GSK Investigational Site

Lille, , France

Site Status

GSK Investigational Site

Mallemort, , France

Site Status

GSK Investigational Site

Marseille, , France

Site Status

GSK Investigational Site

Marseille, , France

Site Status

GSK Investigational Site

Marsillargues, , France

Site Status

GSK Investigational Site

Marssac-sur-Tarn, , France

Site Status

GSK Investigational Site

Mont de Marsen, , France

Site Status

GSK Investigational Site

Montignac, , France

Site Status

GSK Investigational Site

Moulon, , France

Site Status

GSK Investigational Site

Mûrs-Erigné, , France

Site Status

GSK Investigational Site

Nantes, , France

Site Status

GSK Investigational Site

Nantes, , France

Site Status

GSK Investigational Site

Nîmes, , France

Site Status

GSK Investigational Site

Orthez, , France

Site Status

GSK Investigational Site

Paris, , France

Site Status

GSK Investigational Site

Rennes, , France

Site Status

GSK Investigational Site

Roanna, , France

Site Status

GSK Investigational Site

Saint Genies Des Fontaines, , France

Site Status

GSK Investigational Site

Saint-Etienne, , France

Site Status

GSK Investigational Site

Saint-Julien-des-Landes, , France

Site Status

GSK Investigational Site

Saint-Martin-d'Hères, , France

Site Status

GSK Investigational Site

Saint-Pierre-de-Chandieu, , France

Site Status

GSK Investigational Site

Sisteron, , France

Site Status

GSK Investigational Site

Strasbourg, , France

Site Status

GSK Investigational Site

Tarare, , France

Site Status

GSK Investigational Site

Vieux-Condé, , France

Site Status

GSK Investigational Site

Vourey, , France

Site Status

GSK Investigational Site

Bad Rappenau, Baden-Wurttemberg, Germany

Site Status

GSK Investigational Site

Deggingen, Baden-Wurttemberg, Germany

Site Status

GSK Investigational Site

Mannheim, Baden-Wurttemberg, Germany

Site Status

GSK Investigational Site

Trochtelfingen, Baden-Wurttemberg, Germany

Site Status

GSK Investigational Site

Unterschneidheim, Baden-Wurttemberg, Germany

Site Status

GSK Investigational Site

Wangen, Baden-Wurttemberg, Germany

Site Status

GSK Investigational Site

Weinheim, Baden-Wurttemberg, Germany

Site Status

GSK Investigational Site

Aschaffenburg, Bavaria, Germany

Site Status

GSK Investigational Site

Haag, Bavaria, Germany

Site Status

GSK Investigational Site

Höhenkirchen-Siegertsbrunn, Bavaria, Germany

Site Status

GSK Investigational Site

Ismaning, Bavaria, Germany

Site Status

GSK Investigational Site

Krummenaab, Bavaria, Germany

Site Status

GSK Investigational Site

Künzing, Bavaria, Germany

Site Status

GSK Investigational Site

Landshut, Bavaria, Germany

Site Status

GSK Investigational Site

Munich, Bavaria, Germany

Site Status

GSK Investigational Site

Munich, Bavaria, Germany

Site Status

GSK Investigational Site

Munich, Bavaria, Germany

Site Status

GSK Investigational Site

Munich, Bavaria, Germany

Site Status

GSK Investigational Site

Munich, Bavaria, Germany

Site Status

GSK Investigational Site

Munich, Bavaria, Germany

Site Status

GSK Investigational Site

Nuremberg, Bavaria, Germany

Site Status

GSK Investigational Site

Wallerfing, Bavaria, Germany

Site Status

GSK Investigational Site

Bad Kreuznach, Hesse, Germany

Site Status

GSK Investigational Site

Frankfurt am Main, Hesse, Germany

Site Status

GSK Investigational Site

Großalmerode, Hesse, Germany

Site Status

GSK Investigational Site

Lollar, Hesse, Germany

Site Status

GSK Investigational Site

Offenbach, Hesse, Germany

Site Status

GSK Investigational Site

Offenbach, Hesse, Germany

Site Status

GSK Investigational Site

Offenbach, Hesse, Germany

Site Status

GSK Investigational Site

Offenbach, Hesse, Germany

Site Status

GSK Investigational Site

Schaafheim, Hesse, Germany

Site Status

GSK Investigational Site

Vellmar, Hesse, Germany

Site Status

GSK Investigational Site

Damme, Lower Saxony, Germany

Site Status

GSK Investigational Site

Hanover, Lower Saxony, Germany

Site Status

GSK Investigational Site

Hanover, Lower Saxony, Germany

Site Status

GSK Investigational Site

Hildesheim, Lower Saxony, Germany

Site Status

GSK Investigational Site

Lüneburg, Lower Saxony, Germany

Site Status

GSK Investigational Site

Paderborn, Lower Saxony, Germany

Site Status

GSK Investigational Site

Winsen/Lohe, Lower Saxony, Germany

Site Status

GSK Investigational Site

Beckum, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Bergkamen, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Borken, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Dortmund, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Duisburg, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Essen, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Euskirchen, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Goch, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Lüdenscheid, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Lünen, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Neuss, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Schwabenheim, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Siegen, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Warendorf, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Deidesheim, Rhineland-Palatinate, Germany

Site Status

GSK Investigational Site

Diez, Rhineland-Palatinate, Germany

Site Status

GSK Investigational Site

Lambrecht, Rhineland-Palatinate, Germany

Site Status

GSK Investigational Site

Rhaunen, Rhineland-Palatinate, Germany

Site Status

GSK Investigational Site

Chemnitz, Saxony, Germany

Site Status

GSK Investigational Site

Dresden, Saxony, Germany

Site Status

GSK Investigational Site

Dresden, Saxony, Germany

Site Status

GSK Investigational Site

Dresden, Saxony, Germany

Site Status

GSK Investigational Site

Freital, Saxony, Germany

Site Status

GSK Investigational Site

Pirna, Saxony, Germany

Site Status

GSK Investigational Site

Schmiedeberg, Saxony, Germany

Site Status

GSK Investigational Site

Itzehoe, Schleswig-Holstein, Germany

Site Status

GSK Investigational Site

Ratzeburg, Schleswig-Holstein, Germany

Site Status

GSK Investigational Site

Wahlstedt, Schleswig-Holstein, Germany

Site Status

GSK Investigational Site

Wilster, Schleswig-Holstein, Germany

Site Status

GSK Investigational Site

Berlin, , Germany

Site Status

GSK Investigational Site

Berlin, , Germany

Site Status

GSK Investigational Site

Hamburg, , Germany

Site Status

GSK Investigational Site

Hamburg, , Germany

Site Status

GSK Investigational Site

Budapest, , Hungary

Site Status

GSK Investigational Site

Miskolc, , Hungary

Site Status

GSK Investigational Site

Belfast, , Ireland

Site Status

GSK Investigational Site

Co. Tipperary, , Ireland

Site Status

GSK Investigational Site

Cork, , Ireland

Site Status

GSK Investigational Site

Dublin, , Ireland

Site Status

GSK Investigational Site

Dublin, , Ireland

Site Status

GSK Investigational Site

Dublin, , Ireland

Site Status

GSK Investigational Site

Dublin, , Ireland

Site Status

GSK Investigational Site

Dublin, , Ireland

Site Status

GSK Investigational Site

Gowran, , Ireland

Site Status

GSK Investigational Site

Kilkenny, , Ireland

Site Status

GSK Investigational Site

Acquaviva Delle Fonti (BA), Apulia, Italy

Site Status

GSK Investigational Site

Ferrara, Emilia-Romagna, Italy

Site Status

GSK Investigational Site

Ravenna, Emilia-Romagna, Italy

Site Status

GSK Investigational Site

Scandiano (RE), Emilia-Romagna, Italy

Site Status

GSK Investigational Site

Rozzano (MI), Lombardy, Italy

Site Status

GSK Investigational Site

Catania, Sicily, Italy

Site Status

GSK Investigational Site

Città Di Castello (PG), Umbria, Italy

Site Status

GSK Investigational Site

Florence, , Italy

Site Status

GSK Investigational Site

La Spezia, , Italy

Site Status

GSK Investigational Site

Lecce, , Italy

Site Status

GSK Investigational Site

Milan, , Italy

Site Status

GSK Investigational Site

Palermo, , Italy

Site Status

GSK Investigational Site

Parma, , Italy

Site Status

GSK Investigational Site

Perugia, , Italy

Site Status

GSK Investigational Site

Rovigo, , Italy

Site Status

GSK Investigational Site

S. Benedetto TR (AP), , Italy

Site Status

GSK Investigational Site

San Giovanni Rotondo FG, , Italy

Site Status

GSK Investigational Site

Sassari, , Italy

Site Status

GSK Investigational Site

Terni, , Italy

Site Status

GSK Investigational Site

Torino, , Italy

Site Status

GSK Investigational Site

Udine, , Italy

Site Status

GSK Investigational Site

Vicenza, , Italy

Site Status

GSK Investigational Site

's-Hertogenbosch, , Netherlands

Site Status

GSK Investigational Site

De Bilt, , Netherlands

Site Status

GSK Investigational Site

Geleen, , Netherlands

Site Status

GSK Investigational Site

Hengelo, , Netherlands

Site Status

GSK Investigational Site

Huizen, , Netherlands

Site Status

GSK Investigational Site

Losser, , Netherlands

Site Status

GSK Investigational Site

Losser, , Netherlands

Site Status

GSK Investigational Site

Rijswijk, , Netherlands

Site Status

GSK Investigational Site

Roelofarendsveen, , Netherlands

Site Status

GSK Investigational Site

Woerden, , Netherlands

Site Status

GSK Investigational Site

Hamar, , Norway

Site Status

GSK Investigational Site

Paradis, , Norway

Site Status

GSK Investigational Site

Skedsmokorset, , Norway

Site Status

GSK Investigational Site

Albaida (Valencia), , Spain

Site Status

GSK Investigational Site

Basurto/Bilbao, , Spain

Site Status

GSK Investigational Site

Benassal (Castellón), , Spain

Site Status

GSK Investigational Site

Benicasim (Castellón), , Spain

Site Status

GSK Investigational Site

Bilbao, , Spain

Site Status

GSK Investigational Site

Cartagena, , Spain

Site Status

GSK Investigational Site

Cáceres, , Spain

Site Status

GSK Investigational Site

El Palmar (Murcia), , Spain

Site Status

GSK Investigational Site

Elche (Alicante), , Spain

Site Status

GSK Investigational Site

Elda-Alicante, , Spain

Site Status

GSK Investigational Site

Figueras, , Spain

Site Status

GSK Investigational Site

Girona, , Spain

Site Status

GSK Investigational Site

Granollers (Barcelona), , Spain

Site Status

GSK Investigational Site

Jerez (Cadiz), , Spain

Site Status

GSK Investigational Site

Madrid, , Spain

Site Status

GSK Investigational Site

Madrid, , Spain

Site Status

GSK Investigational Site

Mataró, , Spain

Site Status

GSK Investigational Site

Málaga, , Spain

Site Status

GSK Investigational Site

Mérida, , Spain

Site Status

GSK Investigational Site

Olleria, Valencia, , Spain

Site Status

GSK Investigational Site

Onda/Castellón, , Spain

Site Status

GSK Investigational Site

Orihuela (Alicante), , Spain

Site Status

GSK Investigational Site

Plasencia, , Spain

Site Status

GSK Investigational Site

Pontevedra, , Spain

Site Status

GSK Investigational Site

Sagunto/Valencia, , Spain

Site Status

GSK Investigational Site

San Juan (Alicante), , Spain

Site Status

GSK Investigational Site

San Vincente Raspeig (Alicante), , Spain

Site Status

GSK Investigational Site

Santa Coloma de Gramanet (Barcelona), , Spain

Site Status

GSK Investigational Site

Santa Cruz de Tenerife, , Spain

Site Status

GSK Investigational Site

Tereul, , Spain

Site Status

GSK Investigational Site

Toledo, , Spain

Site Status

GSK Investigational Site

Torrelavega/Santander, , Spain

Site Status

GSK Investigational Site

Valencia, , Spain

Site Status

GSK Investigational Site

Valencia, , Spain

Site Status

GSK Investigational Site

Valencia, , Spain

Site Status

GSK Investigational Site

Valladolid, , Spain

Site Status

GSK Investigational Site

Vallda (Valencia), , Spain

Site Status

GSK Investigational Site

Villajoyosa - Alicante, , Spain

Site Status

GSK Investigational Site

Zamora, , Spain

Site Status

GSK Investigational Site

Zaragoza, , Spain

Site Status

GSK Investigational Site

Älta, , Sweden

Site Status

GSK Investigational Site

Degerberga, , Sweden

Site Status

GSK Investigational Site

Gimo, , Sweden

Site Status

GSK Investigational Site

Malmo, , Sweden

Site Status

GSK Investigational Site

Stockholm, , Sweden

Site Status

GSK Investigational Site

Aberdeen, Aberdeenshire, United Kingdom

Site Status

GSK Investigational Site

Sandy, Bedfordshire, United Kingdom

Site Status

GSK Investigational Site

Reading, Berkshire, United Kingdom

Site Status

GSK Investigational Site

Llanelli, Carmarthenshire, United Kingdom

Site Status

GSK Investigational Site

Warrington, Cheshire, United Kingdom

Site Status

GSK Investigational Site

Bournemouth, Dorset, United Kingdom

Site Status

GSK Investigational Site

Poole, Dorset, United Kingdom

Site Status

GSK Investigational Site

Barry, Glamorgan, United Kingdom

Site Status

GSK Investigational Site

Cardiff, Glamorgan, United Kingdom

Site Status

GSK Investigational Site

Hemel Hempstead, Hertfordshire, United Kingdom

Site Status

GSK Investigational Site

Stevenage, Hertfordshire, United Kingdom

Site Status

GSK Investigational Site

Airdrie, Lanarkshire, United Kingdom

Site Status

GSK Investigational Site

Glasgow, Lanarkshire, United Kingdom

Site Status

GSK Investigational Site

Bolton, Lancashire, United Kingdom

Site Status

GSK Investigational Site

Chorley, Lancashire, United Kingdom

Site Status

GSK Investigational Site

Edinburgh, Midlothian, United Kingdom

Site Status

GSK Investigational Site

Wellingborough, Northamptonshire, United Kingdom

Site Status

GSK Investigational Site

Nottingham, Nottinghamshire, United Kingdom

Site Status

GSK Investigational Site

Haverfordwest, Pembrokeshire, United Kingdom

Site Status

GSK Investigational Site

Frome, Somerset, United Kingdom

Site Status

GSK Investigational Site

Crawley, Sussex West, United Kingdom

Site Status

GSK Investigational Site

Bradford, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Argentina South Korea United States Austria Belgium Canada Czechia Denmark Finland France Germany Hungary Ireland Italy Netherlands Norway Spain Sweden United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, Haffner SM, Levy D, Lachin JM, Berry RA, Heise MA, Jones NP, Freed MI. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care. 2002 Oct;25(10):1737-43. doi: 10.2337/diacare.25.10.1737.

Reference Type RESULT
PMID: 12351470 (View on PubMed)

Viberti G, Lachin J, Holman R, Zinman B, Haffner S, Kravitz B, Heise MA, Jones NP, O'Neill MC, Freed MI, Kahn SE, Herman WH; ADOPT Study Group. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. Diabet Med. 2006 Dec;23(12):1289-94. doi: 10.1111/j.1464-5491.2006.02022.x.

Reference Type RESULT
PMID: 17116177 (View on PubMed)

Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006 Dec 7;355(23):2427-43. doi: 10.1056/NEJMoa066224. Epub 2006 Dec 4.

Reference Type RESULT
PMID: 17145742 (View on PubMed)

Kahn SE, Zinman B, Haffner SM, O'Neill MC, Kravitz BG, Yu D, Freed MI, Herman WH, Holman RR, Jones NP, Lachin JM, Viberti GC; ADOPT Study Group. Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. Diabetes. 2006 Aug;55(8):2357-64. doi: 10.2337/db06-0116.

Reference Type RESULT
PMID: 16873701 (View on PubMed)

Zinman B, Kahn SE, Haffner SM, O'Neill MC, Heise MA, Freed MI; ADOPT Study Group. Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes. 2004 Dec;53(12):3193-200. doi: 10.2337/diabetes.53.12.3193.

Reference Type RESULT
PMID: 15561950 (View on PubMed)

El-Damanawi R, Stanley IK, Staatz C, Pascoe EM, Craig JC, Johnson DW, Mallett AJ, Hawley CM, Milanzi E, Hiemstra TF, Viecelli AK. Metformin for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2024 Jun 4;6(6):CD013414. doi: 10.1002/14651858.CD013414.pub2.

Reference Type DERIVED
PMID: 38837240 (View on PubMed)

Gnesin F, Thuesen ACB, Kahler LKA, Madsbad S, Hemmingsen B. Metformin monotherapy for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2.

Reference Type DERIVED
PMID: 32501595 (View on PubMed)

Lachin JM, Viberti G, Zinman B, Haffner SM, Aftring RP, Paul G, Kravitz BG, Herman WH, Holman RR, Kahn SE; ADOPT Study Group. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clin J Am Soc Nephrol. 2011 May;6(5):1032-40. doi: 10.2215/CJN.09291010. Epub 2011 Mar 31.

Reference Type DERIVED
PMID: 21454723 (View on PubMed)

Kahn SE, Haffner SM, Viberti G, Herman WH, Lachin JM, Kravitz BG, Yu D, Paul G, Holman RR, Zinman B; Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2010 Jan;33(1):177-83. doi: 10.2337/dc09-1661. Epub 2009 Oct 6.

Reference Type DERIVED
PMID: 19808911 (View on PubMed)

Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G; Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008 May;31(5):845-51. doi: 10.2337/dc07-2270. Epub 2008 Jan 25.

Reference Type DERIVED
PMID: 18223031 (View on PubMed)

Study Documents

Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.

Document Type: Informed Consent Form

View Document

Document Type: Statistical Analysis Plan

View Document

Document Type: Study Protocol

View Document

Document Type: Clinical Study Report

View Document

Document Type: Individual Participant Data Set

View Document

Document Type: Dataset Specification

View Document

Document Type: Annotated Case Report Form

View Document

Related Links

Access external resources that provide additional context or updates about the study.

https://www.clinicalstudydatarequest.com

Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

49653/048

Identifier Type: -

Identifier Source: org_study_id